Halozyme licenses drug-delivery technology to Roche for $25m upfront

By Maggie Lynch

- Last updated on GMT

(Image: Getty/pixelfit)
(Image: Getty/pixelfit)

Related tags Roche Drug delivery Clinical development Technology Immuno-oncology

Halozyme will provide its drug-delivery technology, Enhanze, to Roche to be used in the development of an undisclosed clinical stage target.

Enhanze technology is based on recombinant human hyaluronidase (rHuPH20) enzyme that temporarily degrades hyaluronan​, a chain of natural sugars in the body, which aids in the dispersion and absorption of injected therapeutic drugs.

Halozyme states that this drug-delivery technology may allow for more efficient absorption through subcutaneous administration, and reduce the need for multiple injections.

Roche and Halozyme have been collaborating and engaged in licensing agreements for the Enhanze technology since 2006​. Using Enhanze, Roche developed multiple drugs including Rituxan (rituximab) in the US, and is awaiting approval on other therapies.

Per the agreement, Halozyme will receive $25m (€22m) upfront from Roche with potential for additional payments up to $160m to $165m per target based upon achievement of development, regulatory, and sales-based milestones. Roche has the option to select two additional targets to be nominated within four years.

Halozyme will receive a nomination fee for two additional new target nominations, and royalties on sales of commercialized products.

Concentrating on partnerships

In 2010, Halozyme cut its workforce​ by 25% to focus on strategic alliances and developments, including the licensing of its technology on external projects.

Bristol-Myers Squibb has also collaborated with Halozyme, in 2017, to develop 11 immuno-oncology drugs​ for subcutaneous administration using Enhanze technology. 

According to a spokesperson for the company, Halozyme has licensed the technology to eight leading pharmaceutical and biotech companies, including Baxalta (now part of Shire), Pfizer, Janssen, AbbVie, Eli Lilly and Alexion. It has been used in the development of 53 potential drug targets in total.

Related news

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers